| 1 |
33531669 | Author Correction: ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions. | 2021 Mar |
1 |
| 2 |
33768672 | Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma. | 2021 May |
1 |
| 3 |
34270745 | Dermatan sulphate is an activating ligand of anaplastic lymphoma kinase. | 2021 Dec 28 |
2 |
| 4 |
34606829 | Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signaling. | 2021 Nov 19 |
1 |
| 5 |
31559892 | A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement. | 2020 |
2 |
| 6 |
31585938 | Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. | 2020 Jan 1 |
1 |
| 7 |
31641223 | Rapid detection and genotyping of ALK fusion variants by adapter multiplex PCR and high-resolution melting analysis. | 2020 Jan |
4 |
| 8 |
31706006 | Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. | 2020 Feb 1 |
1 |
| 9 |
31734646 | Anaplastic Lymphoma Kinase Regulates Internalization of the Dopamine D2 Receptor. | 2020 Feb |
4 |
| 10 |
31736340 | Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer. | 2020 Jan 1 |
2 |
| 11 |
31783178 | Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma. | 2020 Mar |
1 |
| 12 |
31804301 | A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors. | 2020 Jan |
5 |
| 13 |
31804622 | The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. | 2020 Mar |
2 |
| 14 |
31902709 | Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402]. | 2020 Feb 15 |
1 |
| 15 |
31943796 | Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. | 2020 Mar |
1 |
| 16 |
31956933 | KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth. | 2020 Oct |
2 |
| 17 |
31961053 | Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. | 2020 Mar |
4 |
| 18 |
32021525 | Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. | 2020 |
1 |
| 19 |
32041944 | Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. | 2020 Feb 10 |
1 |
| 20 |
30664791 | ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions. | 2019 Feb |
2 |
| 21 |
31341009 | ELP3 Acetyltransferase is phosphorylated and regulated by the oncogenic anaplastic lymphoma kinase (ALK). | 2019 Aug 15 |
2 |
| 22 |
31616158 | Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. | 2019 |
1 |
| 23 |
31616196 | TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations. | 2019 |
2 |
| 24 |
31633304 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. | 2019 Dec |
3 |
| 25 |
31737634 | Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. | 2019 |
1 |
| 26 |
31749991 | Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review. | 2019 |
3 |
| 27 |
31857951 | New generation anaplastic lymphoma kinase inhibitors. | 2019 Nov |
2 |
| 28 |
31857953 | Brain metastases in oncogene-driven non-small cell lung cancer. | 2019 Nov |
1 |
| 29 |
30004444 | Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase. | 2018 Jul 2 |
1 |
| 30 |
30061385 | Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α). | 2018 Aug 14 |
1 |
| 31 |
30127638 | ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells. | 2018 |
1 |
| 32 |
27078848 | CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. | 2016 May 17 |
3 |
| 33 |
27531800 | [Effect of Tyrosine Phosphorylation Sites of Oncogenic Protein NPM-ALK on Cell Cycle and Its Related Mechanisms]. | 2016 Aug |
2 |
| 34 |
25978431 | NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair. | 2015 May 15 |
2 |
| 35 |
25026277 | The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. | 2014 Jul 30 |
1 |
| 36 |
23022960 | Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma. | 2013 Jan |
2 |
| 37 |
23490651 | Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer. | 2013 May |
1 |
| 38 |
23730215 | Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. | 2013 Jun |
11 |
| 39 |
23777859 | Anaplastic lymphoma kinase: "Ligand Independent Activation" mediated by the PTN/RPTPβ/ζ signaling pathway. | 2013 Oct |
2 |
| 40 |
21844131 | Targeted therapy for NSCLC: ALK inhibition. | 2012 Jun |
1 |
| 41 |
22203728 | CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. | 2012 Mar |
1 |
| 42 |
21045017 | Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. | 2011 Feb |
2 |
| 43 |
21213368 | ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. | 2011 Mar |
3 |
| 44 |
21297104 | Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. | 2011 Feb |
3 |
| 45 |
21343335 | HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas. | 2011 Apr |
1 |
| 46 |
21703420 | Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein. | 2011 Jul |
1 |
| 47 |
19887368 | Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry. | 2010 Jan 1 |
6 |
| 48 |
20393185 | Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. | 2010 Jul |
1 |
| 49 |
20554525 | Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. | 2010 Aug 20 |
1 |
| 50 |
20632993 | Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. | 2010 Sep 15 |
1 |